Am J Pathol 2002, 161: 1991–6.PubMed 23. Laakso M, Loman N, Borg A, Isola J: Cytokeratin 5/14-positive breast

cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 2005, 18: 1321–8.CrossRefPubMed 24. Birnbaum D, Bertucci F, Ginestier C, Tagett R, Jacquiemier J, Charafe-Jauffret E: Basal and luminal breast cancer: basic or luminous? Int J Oncol 2004, 25: 249–258.PubMed 25. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, 14: 1368–76.CrossRefPubMed 26. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr: Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985,

109: 716–21.PubMed 27. Gould VE, Koukoulis GK, check details Jansson DS, Nagle RB, Franke WW, Moll R: Coexpression patterns of vimentin and glial filament protein with cytokeratins in the normal, hyperplasitc and neoplastic breast. Am J Pathol 1990, 137: 1143–1155.PubMed 28. Heatley M, Whiteside C, Maxwell P, Toner P: Vimentin expression in benign and malignant breast epithelium. J Clin Pathol 1993, 46: 441–445.CrossRefPubMed 29. Seshadri R, Raymond WA, Leong AS, Horsfall DJ, McCaul K: Vimentin expression is not associated with poor prognosis in breast cancer. Int J Cancer 1996, 67: 353–6.CrossRefPubMed 30. Chen MH, Yip GW, Tse GM, Moriya T, Lui PC, Zin ML, Bay BH, Tan PH: Expression of basal keratins and vimentin in breast cancers of young women correlates with adverse GM6001 concentration pathologic parameters. Mod Pathol 2008, 21: 1183–91.CrossRefPubMed 31. Liu ZB, Wu J, Ping B, Feng LQ, Lu JS, Shen KW, Shen ZZ, Shaol ZM: Basal cytokeratin expression in relation to immunohistochemical and clinical characterization in breast cancer patients with triple negative phenotype. Tumori 2009, 95: 53–62.PubMed 32. Rakha EA,

Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Adenosine triphosphate Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO: Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009, 15: 2302–10.CrossRefPubMed 33. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl PO, Lundin M, Krogh M, Kataja P, Borg A, Fernö M, Isola J: Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 2007, 9: R16.CrossRefPubMed 34. Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD: Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007, 7: 134.CrossRefPubMed 35. Potemski P, Kusinska R, Watala C, Pluciennik E, Bednarek AK, Kordek R: Prognostic relevance of basal cytokeratins expression in operable breast cancer.